Molecular Templates, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTEM research report →
Price Chart
About the company
Molecular Templates, Inc. (MTEM) is a clinical-stage biopharmaceutical firm dedicated to the identification and progression of biological therapies for oncology and other significant health conditions. The company's core development strategy relies on its unique engineered toxin body (ETB) drug platform to construct a robust pipeline of treatments.
- CEO
- Eric E. Poma
- IPO
- 2005
- Employees
- 62
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on MTEM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $658
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.61
- Div Yield
- 0.00%
- Gross Margin
- 87.94%
- Op Margin
- -18.26%
- Net Margin
- -14.18%
- ROE
- 148.79%
- ROIC
- -50.86%
Latest fiscal year · YoY change
- Revenue
- $57.31M+190.1%
- Gross Profit
- $50.40M+321.6%
- Op Income
- $-10,466,000
- Net Income
- $-8,124,000+91.2%
- EPS
- $-1.80+92.7%
- OCF Growth
- +53.0%
- FCF Growth
- +54.4%
- 52W High
- $1.59
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.26
- Beta
- 1.53
- RSI (14)
- 29
- Avg Volume
- 2.43K
No earnings-call transcripts are available for MTEM yet.
- Free Float
- 86.1%
- Shares Outstanding
- 6.58M
- Float Shares
- 5.67M
of shares held by institutions
23 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 38.13K | ▼ 1.51K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 24 | BIOTECH TARGET N V | sell | 1,279,820 |
| Sep 27, 24 | LALANDE KEVIN M. | other | 1,000 |
| Sep 27, 24 | Gruia Gabriela | other | 1,000 |
| Sep 27, 24 | SELICK HAROLD E | other | 1,000 |
| Sep 27, 24 | HOFFMANN DAVE | other | 1,000 |
| Sep 27, 24 | Sanders Corazon (Corsee) D. | other | 1,000 |
| Apr 2, 24 | BIOTECH TARGET N V | buy | 250,000 |
| Apr 2, 24 | BIOTECH TARGET N V | buy | 769,334 |
| Apr 2, 24 | BIOTECH TARGET N V | buy | 134,667 |
| Apr 2, 24 | LALANDE KEVIN M. | other | 1,154,154 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MTEM coverage
Recent articles, reports, and earnings notes.
No research on MTEM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MTEM report →RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
globenewswire.com · Jul 16
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
globenewswire.com · Dec 19
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
globenewswire.com · Dec 2
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
globenewswire.com · Aug 14
Molecular Templates, Inc. Provides Interim Update
globenewswire.com · Jun 3
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
globenewswire.com · May 15
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
globenewswire.com · Apr 9
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
globenewswire.com · Mar 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.